Hangzhou Tigermed Consulting Co., Ltd. announced that its board has approved a 2026 Restricted A Share Incentive Scheme, an assessment framework and a package of implementation authorisations, all pending shareholder approval at an extraordinary general meeting.

Scheme Size and Source • Up to 9.50 million repurchased A shares—about 1.10 % of the current 861.03 million outstanding shares—will be granted in a single tranche. • The equity will be sourced entirely from shares the company buys back on the secondary market, avoiding new issuance and dilution beyond the stated percentage cap.

Participant Profile • 513 individuals will be eligible: executive directors, senior managers and core technical or business staff. • Key grantees include Executive Director & General Manager Wen Zengyu (207,900 shares), Employee Director & Co-President Wu Hao (159,900), COO Peng Yifei (123,000) and CFO Yang Chengcheng (94,600). • Independent directors, 5 %-plus shareholders, the de-facto controller and their immediate families are excluded.

Pricing and Vesting Mechanics • Grant price is fixed at RMB 39.32 per share—no lower than 50 % of recent average market prices and above par value. • Validity extends up to 60 months, with vesting set at 40 % / 40 % / 20 % after 12, 24 and 36 months, respectively. • Each vesting batch carries an additional three-month lock-up. Directors and senior managers remain subject to statutory disposal limits (≤25 % of holdings per year during and six months after tenure).

Performance Hurdles • Vesting is contingent on company-wide net-profit growth versus FY 2025: – 2026: ≥60 % growth for full vesting (≥45 % for partial). – 2027: ≥155 % growth (≥103 % for partial). – 2028: ≥240 % growth (≥170 % for partial). • Individual vesting also depends on annual performance ratings; only top-tier assessments (A+ or A) receive full allocation.

Financial Impact • Total non-cash compensation expense is estimated at RMB 79.14 million (≈USD 11 million), amortised as follows: – 2026: RMB 13.09 million – 2027: RMB 44.68 million – 2028: RMB 17.54 million – 2029: RMB 3.83 million • Management expects the motivational effect of the plan to outweigh the modest profit impact.

Governance and Timetable • The board seeks shareholder authorisation to adjust share numbers or prices for corporate actions, execute grants and handle vesting, amendments or termination. • The grant date will fall within 60 days after EGM approval, subject to compliance blackout periods.

Regulatory Position • As the plan uses repurchased shares and involves no option issuance, it is not governed by Hong Kong Listing Rule Chapter 17. The company will monitor any connected-transaction implications and maintain public-float compliance.

Shareholders and potential investors are advised that the incentive plan remains subject to EGM approval; caution is warranted when dealing in Tigermed’s shares.